期刊文献+

肺动脉高压治疗进展 被引量:2

原文传递
导出
摘要 肺动脉高压(pulmonary arterial hypertension,PAH)是以肺小动脉收缩、血管壁重塑和原位血栓病灶形成为主要特征的一种疾病。病程中PAH进行性加重,预后较差。其与进行性右性心力衰竭、过早死亡有关。临床主要表现为呼吸困难、胸痛、乏力、气促、晕厥、咯血等。PAH是一种极度恶性的疾病,其致残率与致死率都非常高,严重危害患者的生命。近十余年来人们对PAH发病机制的研究报道较多,其治疗也取得了一定的进展,现就近年来国内外有关PAH治疗方面的进展进行综述。
出处 《中国综合临床》 2012年第10期1113-1115,共3页 Clinical Medicine of China
  • 相关文献

参考文献31

  • 1Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension [J].N Engl J Med, 2004, 351 (14) : 1425- 1436.
  • 2Chin KM, Rubin LJ. Pulmonary arterial hypertension [J]. J Am Coil Cardiol,2008,51 (16) :1527-1538.
  • 3Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension [ J ]. Am Coil Cardiol,2005,46(4) :697-704.
  • 4Runo JR, Loyd JE. Primary pulmonary hypertension [ J]. Lancet, 2003,361 (9368) :1533-1544.
  • 5Gaine SP,Rubin LJ. Primary pulmonary hypertension [ J]. Lancet, 1998,352(9129) :719-725.
  • 6Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines [J]. Chest,2004,126(1 Suppl) :35S-62S.
  • 7Ogata M, Obe M, Shirato K, et al. Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension [ J ]. Jpn C irc J, 1993,57 (1) :63- 69.
  • 8McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy [J]. Circulation .2002_ 106( 12 ), 1477-1482.
  • 9Simonneau G, Barst R J, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension : a double-blind, randomized, placebo-controlled trim [ J]. Am J Respir Crit Care Med ,2002,165 ( 6 ) : 800 -804.
  • 10Galie N, Humbert M, Vachi~ry JL, et al. Effects of berapmst sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension : a randomized, double-blind, placebo- cantrolled trial [ J ]. J Am Coil Cardiol,2002,39 (9) :1496-1502.

二级参考文献1

共引文献2

同被引文献19

  • 1Stummvoll GH. Current treatment options in systemic Sclerosis (Scleroderma) [J]. Acta Med Austriaca,2002,29( 1 ) :14-19.
  • 2Seibold JR. Scleroderma. In//Ruddy S, Harris ED, Sledge CB. 6th ed. Kelley' s Textbook of Rheumatology [ M]. Philadelphia: Saunders ,2001 : 1211-1239,.
  • 3Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension:the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society( ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) [ J ]. Eur Heart J, 2009,30(20) :2493-2537.
  • 4Denton CP, Cailes JB, Phillips GD, et al. Comparison of Doppler echoeardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis [ J]. Br J Rheumatol, 1997,36(2) :239-243.
  • 5Murata I,Takenaka K, Yoshinoya S, et al. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographie study of 135 Japanese patients [ J]. Chest, 1997,111 ( 1 ) :36-43.
  • 6曾小峰.系统性硬化病.内科学[M].北京:人民卫生出版社,2013:846-849.
  • 7Shah AA, Wigley FM, Hummers LK. Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension [J]. J Rheumatol,2010,37 (1) :98-104.
  • 8张狟,张奉春,董怡.结缔组织病中肺动脉高压临床特点分析[J].中华风湿病学杂志,1999,3(1):5-7. 被引量:71
  • 9系统性硬化病诊断及治疗指南[J].中华风湿病学杂志,2011,15(4):256-259. 被引量:64
  • 10徐雪,楚海燕,梁敏锐,吴文育,王久存,邹和建.系统性硬化症患者体内S100A12和sRAGE的表达及其临床意义[J].临床内科杂志,2012,29(5):320-323. 被引量:1

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部